临床资料 | 试验组(n = 547) | 验证组(n = 219) | |||||
EGFR野生型 (n = 477) | EGFR罕见突变 (n = 70) | p值 | EGFR野生型 (n = 193) | EGFR罕见突变 (n = 26) | p值 | ||
性别 | <0.001 | 0.098 | |||||
女 | 103 (73.6) | 37 (26.4) | 58 (82.9) | 12 (17.1) | |||
男 | 374 (91.9) | 33 (8.1) | 135 (90.6) | 14 (9.4) | |||
年龄 | 63 (56-69) | 63 (55~68) | 0.483 | 64 (57~68) | 59 (51~69) | 0.739 | |
吸烟史 | <0.001 | 0.055 | |||||
有 | 287 (92) | 25 (8) | 98 (92.5) | 8 (7.5) | |||
无 | 190 (80.9) | 45 (19.1) | 95 (84.4) | 18 (15.9) | |||
病理 | <0.001 | 0.025 | |||||
腺癌 | 336 (83.2) | 68 (16.8) | 149 (85.1) | 26 (14.9) | |||
鳞癌 | 111 (99.1) | 1 (0.9) | 34 (100) | 0 (0) | |||
其他 | 30 (96.8) | 1 (3.2) | 10 (100) | 0 (0) | |||
CEA | 0.015 | 0.029 | |||||
阴性 | 424 (88.5) | 55 (11.5) | 180 (89.6) | 21 (10.4) | |||
阳性 | 53 (77.9) | 15 (22.1) | 13 (72.2) | 5 (27.8) | |||
NSE | 0.092 | 0.746 | |||||
阴性 | 52 (94.5) | 3 (5.5) | 23 (92) | 2 (8) | |||
阳性 | 425 (86.4) | 67 (13.6) | 170 (87.6) | 24 (12.4) | |||
CA125 | 0.299 | 0.326 | |||||
阴性 | 187 (85.4) | 32 (14.6) | 99 (86.1) | 16 (13.9) | |||
阳性 | 290 (88.4) | 38 (11.6) | 94 (90.4) | 10 (9.6) | |||
CYFRA21-1 | <0.001 | 0.047 | |||||
阴性 | 268 (82.5) | 57 (17.5) | 125 (85) | 22 (15) | |||
阳性 | 209 (94.1) | 13 (5.9) | 68 (94.4) | 4 (5.6) | |||
proGRP | 0.155 | 0.747 | |||||
阴性 | 236 (85.2) | 41 (14.8) | 90 (87.4) | 13 (12.6) | |||
阳性 | 241 (89.3) | 29 (10.7) | 103 (88.8) | 13 (11.2) | |||
SCC-Ag | <0.001 | 0.001 | |||||
阴性 | 98 (76) | 31 (24) | 17 (68) | 8 (32) | |||
阳性 | 379 (90.7) | 39 (9.3) | 176 (90.7) | 18 (9.3) |